Cite
HARVARD Citation
Graham, L. et al. (2021). Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high‐risk localized prostate cancer. Prostate. 81 (7), pp. 418-426. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Graham, L. et al. (2021). Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high‐risk localized prostate cancer. Prostate. 81 (7), pp. 418-426. [Online].